Skip to main content
Caplight Logo









Medannex Ltd

Medannex Ltd

Private
EdinburghHealthcare & Life Scienceshttps://medannex.org/

Last Round

Grant

May 11, 2026

Total Funding Raised

$29.07M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Medannex Ltd is a biotechnology company that develops novel monoclonal antibody therapeutics to treat cancers and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalmonoclonal antibodydrug discoveryclinical-stage biotechoncology therapeuticsautoimmune disease treatmentbiotechclinical trialsannexin-A1drug developmenttherapeutic pipelinebiotech startupantibody engineeringnon-dilutive funding

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Medannex Ltd Comparables

Compare Medannex Ltd with similar companies based on industry and business-model similarity.

Medannex Ltd comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Netris Pharma
81%
Alligator Bioscience
69%
Phanes Therapeutics
69%

Medannex Ltd Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 11, 2026
GrantJul 25, 2024
Series BAug 17, 2020
Series BMar 5, 2020
GrantJan 1, 2019
Grant
Jun 12, 2018

Key People

Founding team and executive leadership

Ian Abercrombie

Chief Executive Officer

Executive Team

Medannex Ltd Investors

Notable investors and investment history

Medannex Ltd investors
InvestorRounds
Morningside VenturesSeries B
Innovate UKGrant
Morningside GroupSeries B
Scottish Investment Bank (Scottish Enterprise)Series B, Seed, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors grew 102% MoM.

  • May 11, 2026

    $130K grant received from Scottish Investment Bank

Medannex Ltd Filings

Explore SEC and related filing metadata, where available.

Medannex Ltd filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Medannex Ltd's valuation, stock price, and market status.

Is Medannex Ltd a public or private company?

Medannex Ltd is a private company.

What is the current stock price of Medannex Ltd?

Medannex Ltd is a private company with no public stock price. Caplight tracks Medannex Ltd's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Medannex Ltd worth (valuation)?

Valuation information for Medannex Ltd is not publicly available.

Can I buy Medannex Ltd stock?

Medannex Ltd shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Medannex Ltd's last funding round?

Medannex Ltd's most recent funding round was Grant on May 11, 2026.

Who are the main investors in Medannex Ltd?

Key investors in Medannex Ltd include Morningside Ventures.

Will Medannex Ltd IPO soon?

No public IPO plans have been announced for Medannex Ltd.

How can I track Medannex Ltd secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Medannex Ltd's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEdinburgh
Employee Range12
Year Founded2009
Last FundingMay 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?